These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18217792)

  • 1. A surveillance method for the early identification of idiosyncratic adverse drug reactions.
    Etwel FA; Rieder MJ; Bend JR; Koren G
    Drug Saf; 2008; 31(2):169-80. PubMed ID: 18217792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemoline (Cylert): market withdrawal.
    Hogan V
    CMAJ; 2000 Jan; 162(1):106, 110. PubMed ID: 11216184
    [No Abstract]   [Full Text] [Related]  

  • 3. Pemoline hepatotoxicity and postmarketing surveillance.
    Safer DJ; Zito JM; Gardner JE
    J Am Acad Child Adolesc Psychiatry; 2001 Jun; 40(6):622-9. PubMed ID: 11392339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemoline-associated hepatic failure: a critical analysis of the literature.
    Shevell M; Schreiber R
    Pediatr Neurol; 1997 Jan; 16(1):14-6. PubMed ID: 9044395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of risk management plans: a case study of pemoline using pharmacy claims data.
    Morrato EH; Staffa JA
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):104-12. PubMed ID: 16821248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pemoline-associated fulminant liver failure: testing the evidence for causation.
    Berkovitch M; Pope E; Phillips J; Koren G
    Clin Pharmacol Ther; 1995 Jun; 57(6):696-8. PubMed ID: 7781270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemoline therapy resulting in liver transplantation.
    Adcock KG; MacElroy DE; Wolford ET; Farrington EA
    Ann Pharmacother; 1998 Apr; 32(4):422-5. PubMed ID: 9562136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemoline hepatotoxicity in children.
    Marotta PJ; Roberts EA
    J Pediatr; 1998 May; 132(5):894-7. PubMed ID: 9602211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases.
    Park-Wyllie L; van Stralen J; Castillon G; Sherman SE; Almagor D
    Clin Ther; 2017 Oct; 39(10):2006-2023. PubMed ID: 28988700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compliance with FDA recommendations for pemoline.
    Sarkis EH
    J Am Acad Child Adolesc Psychiatry; 2003 Apr; 42(4):383; author reply 383. PubMed ID: 12649623
    [No Abstract]   [Full Text] [Related]  

  • 11. Pemoline in ADHD.
    Winsberg B; Barbato M
    J Am Acad Child Adolesc Psychiatry; 1997 Dec; 36(12):1649-50. PubMed ID: 9401321
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety assessment in pediatric studies.
    Koren G; Elzagallaai A; Etwel F
    Handb Exp Pharmacol; 2011; 205():169-80. PubMed ID: 21882111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of compliance with FDA recommendations for pemoline (Cylert).
    Willy ME; Manda B; Shatin D; Drinkard CR; Graham DJ
    J Am Acad Child Adolesc Psychiatry; 2002 Jul; 41(7):785-90. PubMed ID: 12108802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reaction. Pemoline and dyskinesia.
    Shuster J
    Nursing; 1999 Feb; 29(2):24. PubMed ID: 10085879
    [No Abstract]   [Full Text] [Related]  

  • 15. Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial.
    Bostic JQ; Biederman J; Spencer TJ; Wilens TE; Prince JB; Monuteaux MC; Sienna M; Polisner DA; Hatch M
    J Child Adolesc Psychopharmacol; 2000; 10(3):205-16. PubMed ID: 11052410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inappropriate pemoline therapy leading to acute liver failure and liver transplantation.
    Abbiati C; Vecchi M; Rossi G; Donata MF; de Franchis R
    Dig Liver Dis; 2002 Jun; 34(6):447-51. PubMed ID: 12132793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemoline in adult attention deficit hyperactivity disorder: predictors of nonresponse.
    Heiligenstein E; Anders J
    J Am Coll Health; 1997 Mar; 45(5):225-9. PubMed ID: 9069682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder.
    Stevenson RD; Wolraich ML
    Pediatr Clin North Am; 1989 Oct; 36(5):1183-97. PubMed ID: 2677938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four cases of severe hepatotoxicity associated with pemoline: possible autoimmune pathogenesis.
    Rosh JR; Dellert SF; Narkewicz M; Birnbaum A; Whitington G
    Pediatrics; 1998 May; 101(5):921-3. PubMed ID: 9565425
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.